Melbourne, Apr 29, 2008 (ABN Newswire) - Leading developer of RNA interference (RNAi)-based therapeutics Benitec Limited (ASX: BLT)(PINK: BNIKF) has secured further intellectual property rights that underpin its HIV/AIDS lymphoma therapeutic currently under going clinical trials at City of Hope in Duarte, California. The therapeutic uses RNAi technology covered by Benitec’s patent portfolio.
